Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.

Singh BN, Fu J, Srivastava RK, Shankar S.

PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.

2.

GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft.

Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, Shankar S.

Cancer Lett. 2013 Mar 1;330(1):22-32. doi: 10.1016/j.canlet.2012.11.018. Epub 2012 Nov 28.

3.

Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.

Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK.

Int J Cancer. 2012 Jul 1;131(1):30-40. doi: 10.1002/ijc.26323. Epub 2011 Aug 25.

4.

Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal.

Rodova M, Fu J, Watkins DN, Srivastava RK, Shankar S.

PLoS One. 2012;7(9):e46083. doi: 10.1371/journal.pone.0046083. Epub 2012 Sep 28.

5.

NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.

Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK, Shankar S.

Neuro Oncol. 2013 Jun;15(6):691-706. doi: 10.1093/neuonc/not011. Epub 2013 Mar 12.

6.

Hedgehog signaling drives cellular survival in human colon carcinoma cells.

Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA.

Cancer Res. 2011 Feb 1;71(3):1092-102. doi: 10.1158/0008-5472.CAN-10-2315. Epub 2010 Dec 6.

7.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

PMID:
24094913
8.

Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.

Li SH, Fu J, Watkins DN, Srivastava RK, Shankar S.

Mol Cell Biochem. 2013 Jan;373(1-2):217-27. doi: 10.1007/s11010-012-1493-6. Epub 2012 Nov 6.

PMID:
23129257
9.

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.

Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM.

Clin Cancer Res. 2014 Dec 1;20(23):5937-45. doi: 10.1158/1078-0432.CCR-14-1269. Epub 2014 Oct 2.

10.

Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.

Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S.

PLoS One. 2011;6(8):e24099. doi: 10.1371/journal.pone.0024099. Epub 2011 Aug 31.

11.

Gli as a novel therapeutic target in malignant pleural mesothelioma.

Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B.

PLoS One. 2013;8(3):e57346. doi: 10.1371/journal.pone.0057346. Epub 2013 Mar 6.

12.

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.

Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E.

Prostate. 2012 Nov;72(15):1638-47. doi: 10.1002/pros.22517. Epub 2012 Mar 27.

PMID:
22457212
13.

Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells.

Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K.

Stem Cells Dev. 2012 Nov 1;21(16):2939-48. doi: 10.1089/scd.2012.0016. Epub 2012 Jul 16.

PMID:
22642671
14.

Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.

Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, Srivastava RK.

PLoS One. 2011 Jan 31;6(1):e16530. doi: 10.1371/journal.pone.0016530.

15.

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.

Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I.

Cell Death Dis. 2013 May 9;4:e627. doi: 10.1038/cddis.2013.158.

16.

NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.

Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen PJ, Shankar S, Srivastava RK.

Oncogenesis. 2013 Apr 8;2:e42. doi: 10.1038/oncsis.2013.5.

17.

Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.

Yao J, An Y, Wie JS, Ji ZL, Lu ZP, Wu JL, Jiang KR, Chen P, Xu ZK, Miao Y.

Swiss Med Wkly. 2011 May 31;141:w13208. doi: 10.4414/smw.2011.13208.

18.

Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice.

Moshai EF, Wémeau-Stervinou L, Cigna N, Brayer S, Sommé JM, Crestani B, Mailleux AA.

Am J Respir Cell Mol Biol. 2014 Jul;51(1):11-25. doi: 10.1165/rcmb.2013-0154OC.

PMID:
24450438
19.

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A.

Mol Cancer Ther. 2008 Sep;7(9):2725-35. doi: 10.1158/1535-7163.MCT-08-0573.

20.

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD.

Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk